These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 11106695)

  • 41. Recent studies bring risks, benefits of hormone replacement therapy under scrutiny.
    Friedrich MJ
    J Natl Cancer Inst; 2001 Sep; 93(17):1287-8. PubMed ID: 11535698
    [No Abstract]   [Full Text] [Related]  

  • 42. Hormone therapy and breast cancer: the press-release version of WHI study data.
    Pines A
    Climacteric; 2013 Apr; 16(2):222-5. PubMed ID: 23488525
    [No Abstract]   [Full Text] [Related]  

  • 43. Postmenopausal estrogen-progestin therapy and breast cancer: a clinical response to epidemiological reports.
    Speroff L
    Climacteric; 2000 Mar; 3(1):3-12. PubMed ID: 11910607
    [No Abstract]   [Full Text] [Related]  

  • 44. Menopausal hormone therapy and cancer risk: An overestimated risk?
    Simin J; Tamimi R; Lagergren J; Adami HO; Brusselaers N
    Eur J Cancer; 2017 Oct; 84():60-68. PubMed ID: 28783542
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study.
    DeBono NL; Robinson WR; Lund JL; Tse CK; Moorman PG; Olshan AF; Troester MA
    J Womens Health (Larchmt); 2018 Mar; 27(3):377-386. PubMed ID: 28570827
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Endometrial cancer risk in estrogen users after switching to estrogen-progestin therapy.
    Chubak J; Doherty JA; Cushing-Haugen KL; Voigt LF; Saltzman BS; Hill DA; Beresford SA; Weiss NS
    Cancer Causes Control; 2007 Nov; 18(9):1001-7. PubMed ID: 17653829
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Breast cancer and hormone-replacement therapy in the Million Women Study.
    Crosignani PG
    Maturitas; 2003 Oct; 46(2):91-2. PubMed ID: 14559371
    [No Abstract]   [Full Text] [Related]  

  • 48. Understanding breast density and breast cancer risk.
    Peres J
    J Natl Cancer Inst; 2012 Sep; 104(18):1345-6. PubMed ID: 22984197
    [No Abstract]   [Full Text] [Related]  

  • 49. Critical review of the article by Colditz et al. on 'The use of estrogens and progestins and the risk of breast cancer in postmenopausal women' published in the N.E.J.M. 1995, 332: 1589.
    Sismondi P; Biglia N
    Pharmacol Res; 1995 Dec; 32(6):329-30. PubMed ID: 8736482
    [No Abstract]   [Full Text] [Related]  

  • 50. Breast cancer risk during hormone therapy: experimental versus clinical data.
    Ruan X; Seeger H; Mueck AO
    Minerva Endocrinol; 2012 Mar; 37(1):59-74. PubMed ID: 22382615
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Estrogens, progestins, and risk of breast cancer.
    Pike MC; Wu AH; Spicer DV; Lee S; Pearce CL
    Ernst Schering Found Symp Proc; 2007; (1):127-50. PubMed ID: 18540571
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Breast cancer: the role of hormone therapy.
    Creasman WT
    Semin Reprod Med; 2005 May; 23(2):167-71. PubMed ID: 15852202
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Progesterone receptors--animal models and cell signalling in breast cancer. Implications for breast cancer of inclusion of progestins in hormone replacement therapies.
    Schairer C
    Breast Cancer Res; 2002; 4(6):244-8. PubMed ID: 12473171
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lack of effect modification between estrogen metabolism genotypes and combined hormone replacement therapy in postmenopausal breast cancer risk.
    Rebbeck TR; Troxel AB; Shatalova EG; Blanchard R; Norman S; Bunin G; Demichele A; Schinnar R; Berlin JA; Strom BL
    Cancer Epidemiol Biomarkers Prev; 2007 Jun; 16(6):1318-20. PubMed ID: 17548708
    [No Abstract]   [Full Text] [Related]  

  • 55. Hormone replacement therapy and breast cancer risk.
    Melnikow J
    J Fam Pract; 1995 Nov; 41(5):501-2. PubMed ID: 7595271
    [No Abstract]   [Full Text] [Related]  

  • 56. Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy.
    Johnson KC; Aragaki AK; Jackson R; Reiner A; Sandset PM; Rosing J; Dahm AE; Rosendaal F; Manson JE; Martin LW; Liu S; Kuller LH; Cushman M; Rossouw JE
    Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):418-24. PubMed ID: 26681757
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Menopausal hormones and risk of ovarian cancer.
    Moorman PG; Schildkraut JM; Calingaert B; Halabi S; Berchuck A
    Am J Obstet Gynecol; 2005 Jul; 193(1):76-82. PubMed ID: 16021062
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer.
    Colditz GA
    J Natl Cancer Inst; 1998 Jun; 90(11):814-23. PubMed ID: 9625169
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Hormone replacement therapy in menopause and risk of breast cancer].
    Clavel-Chapelon F; Hill C
    Presse Med; 2000 Oct; 29(31):1688-93. PubMed ID: 11094609
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Breast cancer risk with postmenopausal hormonal treatment.
    Collins JA; Blake JM; Crosignani PG
    Hum Reprod Update; 2005; 11(6):545-60. PubMed ID: 16150813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.